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Following publication of the original article \[[@CR1]\], an error was noted in the GAPDH in the western blot depicted in Figure 4b. The GAPDH lanes for the experiment have been updated. The corrected Fig. [4](#Fig1){ref-type="fig"} can be seen below. Fig. 4Olaparib treatment enhances ADCC using both cetuximab and avelumab without modulation of mAb targets EGFR and PD-L1. **a** Treatment with cetuximab (cet) significantly increased NK-induced lysis of olaparib (ola)-treated BRCA mutant prostate carcinoma (22RV1) cells at 12 h. The addition of anti-CD16 antibody neutralized this increase, confirming that the increased lysis is attributable to ADCC. **b** STING is not expressed in 22RV1 either before or after olaparib treatment. **c** Olaparib treatment did not result in significant modulation of EGFR expression on 22RV1 cells as measured by flow cytometry. **d** Treatment with cetuximab increased NK-induced lysis of olaparib-treated BRCA WT prostate carcinoma cells (DU145) cells. Role of anti-CD16 antibody on increased lysis attributable to ADCC. **e** The PD-L1+ cell line DU145 also underwent NK-induced ADCC in the presence of the anti-PD-L1 antibody avelumab (ave). Lysis of DU145 cells after 12 h in the presence or absence of olaparib and NK, treated with either avelumab or isotype control is shown. **f** STING was upregulated in DU145 following exposure to olaparib. **g** Olaparib treatment did not result in significant modulation of EGFR expression in DU145 cells as measured by flow cytometry. **h** Olaparib treatment did not result in significant modulation of PD-L1 expression in DU145 cells as measured by flow cytometry. These experiments were performed twice with similar results. *p* \< 0.05\*, *p* \< 0.0001\*\*\*\*

The error does not affect the findings of the experiment.
